Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.

Trial Details

NCT ID
NCT04297605
Phase
PHASE1
Sponsor
University of Rochester
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Pembrolizumab
  • Pemetrexed (Chemotherapy)
  • Nab-paclitaxel (Chemotherapy)
Locations (sample)
  • Rochester, New York, United States|43.15478,-77.61556
  • Rochester, New York, United States|43.15478,-77.61556

Key Eligibility Criteria

  • Participants must be \>18 years old at time of diagnosis
  • Histologically confirmed non-small cell lung cancer
  • Clinical staging of IIIc or IV disease.
  • 4A. For patients with stage IIIc disease, patients are ineligible for or refuse standard treatment with platinum-double chemotherapy and radiation.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →